SynthesisPrenatal diagnosis2025
Fetoscopic Laser Ablation of Type II Vasa Previa-Case Report and Systematic Review.
Synthesis in Prenatal diagnosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Fetoscopic Laser Ablation of Type II Vasa Previa-Case Report and Systematic Review.Prenatal diagnosis · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasa previa is a rare but potentially fatal obstetric condition in which fetal vessels traverse the internal cervical os without the protection of placental tissue or Wharton's jelly, making them highly vulnerable to rupture during labor or spontaneous membrane rupture. This can result in rapid fetal exsanguination and death. While current management involves planned cesarean delivery before the onset of labor, fetoscopic laser ablation (FLA) has recently emerged as a minimally invasive alternative for selected cases, particularly type II and III vasa previa, allowing for pregnancy prolongation and potential vaginal delivery. We report the case of a 40-year-old gravida 3 para 0 woman diagnosed with type II vasa previa at 22 + 5 weeks. FLA was performed successfully at 31 + 5 weeks without complications. At 36 + 5 weeks, she experienced spontaneous rupture of membranes and delivered a healthy male neonate via cesarean section at maternal request. To contextualize this case, we conducted a systematic review of 54 cases from the literature. FLA was associated with a 98.1% technical success rate, 50% vaginal delivery rate, and 100% neonatal survival, with no major maternal complications reported. These findings suggest that FLA may offer a safe and effective alternative to preterm cesarean delivery in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.